Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A real world study of apatinib combined with gefitinib in EGFR-positive advanced non-squamous NSCLC
ChiCTR2000039246Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Oct 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and gefitinib in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoints: Progression-free survival and Duration of response. Started Oct 2020; status: recruiting.
02
Drugs
Rivoceranibgefitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000039246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039246.